UNSPSC 51332811: Duoperone

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C28H26F4N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, E84FJ4KW3B chemically known as methanone, (4-fluorophenyl)(1-(3-(2-(trifluoromethyl)-10h-phenothiazin-10-yl)ropyl)-piperidinyl) but generally known as duoperone, which bears US NIH Compound Identifier 43876. European Medicines Agency schedules Duoperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06428MIG.

UNSPSC 51332811 Duoperone, a Commodity code, encompasses pharmaceutical products and drug-management systems that state and local health agencies procure to support public health initiatives, community health programs, and emergency response. Recent solicitations show state and local governments buying naloxone and drug deactivation systems, generic multi-source pharmaceuticals with specific National Drug Codes, and exploring direct-to-manufacturer prescription fulfillment models to optimize cost and supply chain efficiency. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). The mix reflects both direct county procurement and collaborative purchasing arrangements that aggregate demand across multiple state and local members.

Recent activity spans Florida, Texas, and the Upper Midwest. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023—note the date inconsistency in the source) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring vendors to cover shipping costs and comply with E-Verify and workers' compensation insurance requirements. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026 regarding a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, seeking vendor input on direct contracting capabilities outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance released an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), requiring current Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and pricing submissions weighted 75 percent on competitiveness. Contracts awarded under MMCAP are effective July 1, 2026 for two-year terms with optional extensions.